Resistance to Therapies in Hepatocellular Carcinoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (15 July 2024) | Viewed by 588
Special Issue Editor
Interests: hepatocellular carcinoma; pancreatic cancer; drug resistance; tumour microenvironment; immunotherapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Hepatocellular carcinoma (HCC) is one of the most malignant human cancers in Asian countries and all over the world. Prognosis in HCC patients remains very poor, due to the difficulties in early diagnosis, as well as limited effective intervention. Oral chemotherapeutic agents are generally not effective in HCC cells. Targeted therapies, such as multi-kinase inhibitors, are proven to be beneficial to part of the patients, but the benefits minimize due to the primary and acquired resistance of HCC. The efficacy of immunotherapies in HCC is investigational. This Special Issue focuses on the underlying mechanisms involved in the resistance of HCC to different types of pharmacological interventions, including chemotherapy, targeted therapies, and immunotherapies, as well as possible strategies to overcome the resistance. Original and review articles of both clinical and non-clinical studies are welcome.
Dr. Ning Wang
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hepatocellular carcinoma
- resistance
- chemotherapy
- targeted therapy
- immunotherapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
